checkAd

    EQS-News  105  0 Kommentare Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA - Seite 3

    Volta Medical will exhibit at booth #328, featuring a demonstration of the Volta AF-Xplorer software, while a tech suite at #TS266 will spotlight the company’s product vision. In addition, the company will present the poster: “Multi-Pronged Communication And Storage Platform For The Collection, Curation And Annotation Of Per-Procedural Cardiac Electrophysiology Datasets”. The poster discusses a ‘first of its kind’ data collection and enrichment ecosystem that greatly simplifies machine learning training and management in the data rich EP environment. Co-founder and CEO Théophile Mohr Durdez will be participating in the HRX Innovation Panel to discuss the challenges of bringing groundbreaking opportunities to market.

    About Atrial Fibrillation

    The American Heart Association (AHA) defines atrial fibrillation (AF) as a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.1 Approximately 33 million patients worldwide are living with AF.2,3 Even though untreated AF doubles the risk of heart-related deaths and is associated with a 5-fold increased risk for stroke, many patients are unaware that AF is a serious condition.

    About Volta Medical
    Volta Medical is a health technology company developing artificial intelligence software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Founded by three physicians and a data scientist in 2016 in Marseille, Volta’s overarching goal is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data. The company’s solution, AF-Xplorer, is a digital AI companion device and algorithm to assist cardiologists with real-time identification of specific abnormal electrograms, known as dispersed EGMs. AF-Xplorer is CE marked and FDA cleared. For more information, visit the company’s website at www.volta-medical.com.

    Seite 3 von 4



    EQS Group AG
    0 Follower
    Autor folgen
    Verfasst von EQS Group AG
    EQS-News Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA - Seite 3 EQS-News: Volta Medical SAS / Key word(s): Study Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA 18.04.2024 / 14:00 CET/CEST The issuer is solely responsible for the …